Zura Bio to Present at the Leerink Partners Global Healthcare Conference
Zura Bio Limited - Class A Ordinary shares (ZURA)
Company Research
Source: Business Wire
HENDERSON, Nev.--(BUSINESS WIRE)--Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced that members of its senior leadership team will participate in a fireside chat at the Leerink Partners Global Healthcare Conference on Tuesday, March 11, 2025, at 1:40 p.m. ET, and will host investor meetings in Miami, FL.A live webcast and a replay of the presentation will be available on the News & Events page in the Investors & Media section of the Zura Bio website. The presentation will be archived on the website for at least 30 days following the event.ABOUT ZURA BIOZura Bio is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. Currently, Zura Bio is developing three assets which have completed Phase 1/1b studies. The company is developing a portfolio of therapeutic indica
Show less
Read more
Impact Snapshot
Event Time:
ZURA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ZURA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ZURA alerts
High impacting Zura Bio Limited - Class A Ordinary shares news events
Weekly update
A roundup of the hottest topics
ZURA
News
- Zura Bio (NASDAQ:ZURA) was upgraded by analysts at Leerink Partnrs to a "strong-buy" rating.MarketBeat
- Zura Bio (NASDAQ:ZURA) was downgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=ZURA&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a>MarketBeat
- Zura Bio (NASDAQ:ZURA) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $10.00 price target on the stock.MarketBeat
- Zura Bio Reports Third Quarter 2025 Financial Results and Recent Corporate UpdatesBusiness Wire
- Zura Bio (NASDAQ:ZURA) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=ZURA&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> fMarketBeat
ZURA
Earnings
- 11/13/25 - Miss
ZURA
Sec Filings
- 12/17/25 - Form 8-K
- 11/14/25 - Form SCHEDULE
- 11/14/25 - Form SCHEDULE
- ZURA's page on the SEC website